Vaccine development Syva is actively developing a vaccine against Streptococcus suis, presenting a potential collaboration opportunity for joint R&D, co-development, or supply of novel vaccine solutions to expand its veterinary portfolio.

Global reach With subsidiaries in Spain, Portugal, and Mexico and distribution in over 70 countries, there are multiple regional markets and partners ripe for expanded product introductions, channel partnerships, and distributor enablement programs.

Mid-market footprint Revenue in the mid tens of millions and an employee base under 500 positions Syva as a growth-focused, mid-market partner ideal for scalable contracts, white-labelled offerings, and long-term supply agreements.

Digital tools Adoption of SAP, Power BI, WordPress, and Microsoft 365 suggests a data-driven sales approach and efficient operations; leverage CRM/ERP integration for targeted account planning and performance analytics.

Strategic collaborations Recent vaccine collaboration news signals openness to joint ventures and external partnerships; there is an opportunity to propose co-development, licensing, or distribution deals with the right vaccine or biotech partners.